Scott A Lowe

US Patent:

20220193109, Jun 23, 2022

Filed:

Apr 23, 2020

Appl. No.:

17/604864

Inventors:

- New York NY, US
- San Francisco CA, US
Scott LOWE - New York NY, US

International Classification:

A61K 31/7088
A61P 35/00
A61K 31/7068
G01N 33/50
A61K 31/519
C12N 15/113
A61K 31/7135
A61K 31/4412

Abstract:

The present disclosure relates generally to compositions and methods for the treatment of a RAS-mutant cancer. In particular, the present technology relates to administering a therapeutically effective amount of one or more TXNRD1 inhibitors to a subject diagnosed with, or at risk for a RAS-mutant cancer (e.g., RAS-mutant pancreatic cancer).

US Patent:

20210220471, Jul 22, 2021

Filed:

Jul 12, 2019

Appl. No.:

17/259800

Inventors:

- New York NY, US
Scott W. Lowe - New York NY, US

International Classification:

A61K 39/395
C07K 16/28
C07K 16/24
A61K 31/551
A61K 31/4745
A61K 31/517
A61K 31/655
A61K 31/55
A61K 31/4709
A61K 31/5383
A61K 31/473
A61K 31/437
A61K 31/444
A61K 45/06
A61P 35/00

Abstract:

The present technology provides methods for treating and/or preventing pancreatic cancer using inhibitors of Type 2 cytokine signaling. Also disclosed herein are methods for selecting a pancreatic cancer patient for treatment with an inhibitor of Type 2 cytokine signaling. Kits for use in practicing the methods are also provided.

US Patent:

20210205319, Jul 8, 2021

Filed:

Jul 3, 2019

Appl. No.:

17/258054

Inventors:

- New York NY, US
Scott Lowe - New York NY, US

International Classification:

A61K 31/535
A61K 31/519
A61K 31/4523
A61K 31/4184
A61K 31/18
A61K 31/44
A61K 31/185
A61K 31/145
A61K 31/4412
A61K 31/506
A61P 35/00

Abstract:

The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.

US Patent:

20170038384, Feb 9, 2017

Filed:

Jan 8, 2015

Appl. No.:

15/110452

Inventors:

- New York NY, US
Susann Weissmueller - New York NY, US
Scott W. Lowe - New York NY, US
Michael Saborowski - New York NY, US

International Classification:

G01N 33/574
A61K 31/7088
C12Q 1/68
C07K 16/28

Abstract:

PDGFRb inhibitors and the use of such inhibitors to treat mutant p53-expressing tumors are described. The present disclosure encompasses the discovery that mutant p53-induced upregulation of the platelet-derived growth factor receptor b (PDGFRb) contributes to invasion and/or metastasis of tumors expressing mutant p53. Specifically, the present disclosure encompasses the discovery that mutant p53 can disrupt a p73/NF-Y complex (which can repress PDGFRB transcription), leading to transcription of PDGFRb. The present disclosure therefore provides, at least in part, PDGFRb modulators (e.g., activators or inhibitors) for use in medicine, and specifically in diagnosis, treatment and/or prevention (e.g., delay of onset) of certain disorders, e.g., cancer.